- Home
- DMLP vs SPRY Comparison
DMLP vs SPRY Comparison
Compare DMLP & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- SPRY
- Stock Information
- Founded
- DMLP 2003
- SPRY 2015
- Country
- DMLP United States
- SPRY United States
- Employees
- DMLP N/A
- SPRY N/A
- Industry
- DMLP Oil & Gas Production
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- DMLP Energy
- SPRY Health Care
- Exchange
- DMLP Nasdaq
- SPRY Nasdaq
- Market Cap
- DMLP 1.3B
- SPRY 1.4B
- IPO Year
- DMLP N/A
- SPRY N/A
- Fundamental
- Price
- DMLP $26.77
- SPRY $14.43
- Analyst Decision
- DMLP
- SPRY Strong Buy
- Analyst Count
- DMLP 0
- SPRY 4
- Target Price
- DMLP N/A
- SPRY $28.75
- AVG Volume (30 Days)
- DMLP 130.7K
- SPRY 1.5M
- Earning Date
- DMLP 05-08-2025
- SPRY 05-14-2025
- Dividend Yield
- DMLP 11.82%
- SPRY N/A
- EPS Growth
- DMLP N/A
- SPRY N/A
- EPS
- DMLP 2.03
- SPRY N/A
- Revenue
- DMLP $166,824,000.00
- SPRY $97,122,000.00
- Revenue This Year
- DMLP N/A
- SPRY $1.49
- Revenue Next Year
- DMLP N/A
- SPRY $141.68
- P/E Ratio
- DMLP $13.21
- SPRY N/A
- Revenue Growth
- DMLP 12.09
- SPRY 971120.00
- 52 Week Low
- DMLP $25.84
- SPRY $7.55
- 52 Week High
- DMLP $34.88
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- DMLP 34.82
- SPRY 53.24
- Support Level
- DMLP $27.74
- SPRY $14.32
- Resistance Level
- DMLP $28.75
- SPRY $15.50
- Average True Range (ATR)
- DMLP 0.67
- SPRY 0.84
- MACD
- DMLP -0.10
- SPRY 0.12
- Stochastic Oscillator
- DMLP 3.59
- SPRY 72.21
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.